Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/3182
Title: Changes in protein profiles in Bortezomib applied Multiple Myeloma cells
Authors: Şanlı Mohamed, Gülşah
Turan, Taylan
Issue Date: 2011
Publisher: Izmir Institute of Technology
Abstract: Multiple Myeloma is a malignant B-cell neoplasm that is characterized by the accumulation of malignant plasma cells in the bone marrow. Over the recent years, several novel agents have been introduced in the treatment of this disease. Bortezomib is the first of a new class of agents known as proteasome inhibitors. The main objective of the project was basically to both determine the cytotoxic and apoptotic effects of Bortezomib on Multiple Myeloma U-266 cells and compare and explore the differences between Bortezomib applied Multiple Myeloma cells and control group Multiple Myeloma cells, by proteomics studies. In order to achieve our aims in the project, variety of multidisciplinary subjects were come together. Cancer research techniques, biochemical studies at protein level and proteomics were combined in our studies. In this study, our experimental results demonstrated that Bortezomib has antiproliferative and apoptotic effects on MM U-266 cells. On the other hand, the responsible proteins for the effect mechanism of anti-cancer agent on cells were determined by MALDI-TOF-TOF Mass Spectrometry for the first time. According to the mass spectrometric analysis, 37 protein spots were differentially expressed. Among them, five proteins were newly formed, ten proteins lost, twelve proteins were up-regulated and ten proteins were down-regulated as compared to control group (untreated cells).These differential expressed proteins in response to Bortezomib have different important functions ranging from cell signaling transduction, cell cycle regulation, apoptosis to immunity and defense mechanism. In conclusion, it was identified which proteins have a central role behind the effect of Bortezomib on MM U-266 cells. The identified proteins may let to be possible to treat other cancer types by same anticancer agent. The data obtained by this study may also be helpful for medical schools and drug designers and may also provide new treatments.
Description: Thesis (Master)--İzmir Institute of Technology, Chemistry, İzmir, 2011
Includes bibliographical references (leaves: 89-101)
Text in English; Abstract: Turkish and English
xi, 111 leaves
URI: http://hdl.handle.net/11147/3182
Appears in Collections:Master Degree / Yüksek Lisans Tezleri

Files in This Item:
File Description SizeFormat 
T001001.pdfMasterThesis2.72 MBAdobe PDFThumbnail
View/Open
Show full item record

CORE Recommender

Page view(s)

30
checked on Sep 19, 2022

Download(s)

26
checked on Sep 19, 2022

Google ScholarTM

Check


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.